From the Lab to the

World

Faster

At Ark, we are transforming bioprocessing by championing a model-first approach that combines biology, chemistry, and physics with the predictive power of machine learning and AI.

By replacing traditional trial-and-error methods with hybrid models, we empower organizations to predict outcomes, optimize processes, and scale with precision—dramatically reducing R&D timelines, cutting costs, and increasing accessibility to life-saving therapies and innovative products.

Our mission is to revolutionize how molecules move from lab to market, building a future where innovation is accelerated, breakthroughs are affordable, and bioprocessing operates at the speed of possibility.

Founding Team

Building the future of bioprocess

Zheng Huang and Yossi Quint founded Ark with a shared vision: to transform bioprocessing by combining deep domain expertise with bold thinking.

Yossi began his career as a quantitative researcher in finance, where he witnessed the transformative power of predictive modeling. Zheng brought over a decade of experience in biopharmaceuticals, having previously served as the Director of MSAT at Sanofi where he led teams in tech transfer, process modeling, and automation, and saw firsthand the need for more integrated, data-driven approaches.

Together, they started Ark to build the future of bioprocess, harnessing advanced modeling to create faster, more accessible, and more innovative pathways from lab to market.